Patients with ED exhibit varying treatment patterns across races

In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38, P = .002).

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.